Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016

Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016
Published Jun 30, 2016
52 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016, provides in depth analysis on Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted pipeline therapeutics.

The report provides comprehensive information on the Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)
- The report reviews Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics and enlists all their major and minor projects
- The report assesses Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7)<

  
Source:
Document ID
GMDHC0148TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Overview61
Therapeutics Development73
  Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Products under Development by Stage of Development71
  Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Products under Development by Therapy Area81
  Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Products under Development by Indication91
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Products under Development by Companies122
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Therapeutics Assessment146
  Assessment by Monotherapy/Combination Products141
  Assessment by Mechanism of Action151
  Assessment by Route of Administration162
  Assessment by Molecule Type182
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Companies Involved in Therapeutics Development203
  Genentech, Inc.201
  Protagonist Therapeutics Inc.211
  Takeda Pharmaceutical Company Limited221
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Drug Profiles2311
  etrolizumab Drug Profile232
  PTG-100 Drug Profile252
  Small Molecule to Antagonize Integrin Alpha4 and Beta7 for Inflammatory Bowel Disease Drug Profile271
  Small Molecules to Antagonize Integrin Alpha4 and Integrin Beta7 for Inflammatory Bowel Disease Drug Profile281
  vedolizumab Drug Profile295
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Dormant Projects341
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Discontinued Products351
Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) Featured News &Press Releases3615
  May 24, 2016: Takeda Presents Analyses From Vedolizumab Data in Ulcerative Colitis at 2016 Digestive Disease Week Annual Meeting361
  May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-100 at Digestive Disease Week 2016371
  Mar 19, 2016: New Data Presented at European Crohn's and Colitis Organisation Scientific Meeting on Efficacy of Long-Term Vedolizumab Treatment371
  Jan 08, 2016: Protagonist Therapeutics Initiates Phase 1 Study with Oral Peptide PTG-100381
  Oct 19, 2015: Takeda Presents Vedolizumab Data at the 2015 American College of Gastroenterology Annual Meeting and United European Gastroenterology Week392
  Jul 10, 2015: NICE recommends treatment for severe Crohn s disease411
  May 19, 2015: New biologic treatment for ulcerative colitis ENTYVIO (vedolizumab) now available in Canada after key work by Canadian researchers411
  May 19, 2015: New biologic treatment for ulcerative colitis ENTYVIO now available in Canada after key work by Canadian researchers422
  Mar 13, 2015: Treatment for chronic painful bowel condition to get NHS funding approval441
  Nov 10, 2014: Encycle Therapeutics developing lead molecule to tackle inflammatory bowel disease441
  Nov 10, 2014: Partnership announcement to tackle inflammatory bowel disease451
  Oct 02, 2014: Takeda Presents New Interim Phase 3 Maintenance Data that Support the Long-Term Efficacy of Vedolizumab in Patients with Ulcerative Colitis and Crohn s Disease461
  Jun 16, 2014: ENTYVIO (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease471
  May 28, 2014: Takeda Receives European Commission Marketing Authorisation for Entyvio (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease481
  May 20, 2014: FDA Approves Takeda's Entyvio for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease492
Appendix512
  Methodology511
  Coverage511
  Secondary Research511
  Primary Research511
  Expert Panel Validation511
  Contact Us511
  Disclaimer521

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Integrin-Beta-7-Gut-Homing-Receptor-Beta-Subunit-or-ITGB7-Pipeline-Review-H1-2016-2088-16078>
  
APA:
Global Markets Direct - Market Research. (2016). Integrin Beta 7 (Gut Homing Receptor Beta Subunit or ITGB7) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Integrin-Beta-7-Gut-Homing-Receptor-Beta-Subunit-or-ITGB7-Pipeline-Review-H1-2016-2088-16078>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.